Roche's Tecentriq crosses the finish line first in adjuvant lung cancer, potentially kicking off gold rush
While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
